Evaluation of haemostasis impairment in early stages of liver cirrhosis: A clinical study

HAEMA

Volumn 7, Issue 4, 2004, Pages 471-478

  Papadopoulos, Vassilios ^a   Kartasis, Zafiris ^a   Mimidis, Konstantinos ^a,b   Papantoniou, Stephanos ^a   Baka, Maria ^a   Kotsiou, Stamatia ^a   Bourikas, Georgios ^a   Kartalis, Georgios ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b NONE   (Greece)

Author keywords

AICF; Child Pughscore; Coagulation; Fibrinolysis; PFA 100

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FATTY ACID BINDING PROTEIN; FIBRINOGEN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TISSUE FACTOR PATHWAY INHIBITOR;

ACCELERATED INTRAVASCULAR COAGULATION AND FIBRINOLYSIS; ADULT; AGED; ARTICLE; AUTOANALYZER; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CHILD PUGH SCORE; CLINICAL ARTICLE; COMMON COAGULATION PATHWAY; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; EXTRINSIC COAGULATION PATHWAY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INTERNATIONAL STANDARD UNIT; LIVER CIRRHOSIS; MALE; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN ACTIVITY; PROTHROMBIN RATIO; PROTHROMBIN TIME; SCORING SYSTEM; THROMBOCYTE FUNCTION;

EID: 6344262191     PISSN: 11082682     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation Disorders in Liver Disease. Semin Liver Dis 2002; 22: 83-96.
2. Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with non-alcoholic chronic liver disease. Am J Gastroenterol 2000; 95: 2936-2939.
3. Koike Y, Yoneyama A, Shirai J et al. Evaluation of thrombopoiesis in thrombocytopenic disorder by simultaneous measurement of reticulated platelets of whole blood and serum thrombopoietin concentrations. Thromb Haemost 1998; 79: 1106-1110.
4. Kawasaki T, Takeshita A, Souda K et al. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Am J Gastroenterol 1999; 94: 1918-1922.
5. Samuel H, Nardi M, Karpatkin M et al. Differentiation of autoimmune thrombocytopenia from thrombocytopenia associated with immune complex disease: systemic lupus erythematosus, hepatitis-cirrhosis, and HIV-1 infection by platelet and serum immunological measurements. Br J Haematol 1999; 105: 1086-1091.
6. Paramo JA, Rocha E. Hemostasis in advanced liver disease. Semin Thromb Hemost 1993; 19: 184-190.
7. Dumontier I, Alhenc-Gelas M, Chatellier G et al. Modifications des taux des inhibiteurs plasmatiques de la coagulation au cours de la cirrhose. Gastroenterol Clin Biol 1992; 16: 120-125.
8. Pereira SP, Langley PG, Williams R. The management of abnormalities of hemostasis in acute liver failure. Semin Liver Dis 1996; 16: 403-414.
9. Violi F, Ferro D, Basili S et al. Association between low-grade disseminated intravascular coagulation and endotoxinemia in patients with liver cirrhosis. Gastroenterology 1995; 109: 531-539.
10. Van Thiel DH, George M, Fareed J. Low levels of thrombin activatable fibrinolusis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost 2001; 85: 667-670.
11. Joist JH. AICF and DIC in liver cirrhosis: Expression of a hypercoagulable state. Am J Gastroenterol 1999; 94: 2801-2803.
12. Rovert A, Chazouilleres O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio? Hepatology 1996; 24: 1392-1394.
13. Chazoullieres O, Robert A. Normalizing the Prothrombin Time. Hepatology 2000; 32: 861.
14. Ben-Ari Z, Osman E, Hutton RA, Burroughs AK. Disseminated intravascular coagulation in liver cirrhosis: fact or fiction? Am J Gastroenterol 1999; 94: 2977-2982.
15. Kemkes-Matthes B, Matthes KJ. Protein Z, a new haemostatic factor, in liver diseases. Haemostasis 1995; 25: 312-316.
16. Wuillemin WA, Gasser KM, Zeerleder SS, Lammle B. Evaluation of a Platelet Function Analyzer (PFA-100) in patients with a bleeding tendency. Swiss Med Wkly 2002; 132: 443-448.
17. Escolar G, Cases A, Vinas M et al. Evaluation of aquired platelet dysfunction in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation. Haematologica 1999; 84: 614-619.
18. Pihusch R, Rank A, Gohring P et al. Platelet function rather than plasmatic coagulation explains hypercoagulable state in cholestatic liver disease. J Hepatol 2002; 37: 548-555.
19. Rubin MH, Weston MJ, Langley MH et al. Platelet function in chronic liver disease: relationship to disease severity. Dig Dis Sci 1979; 24: 197-202.
20. Ingeberg S, Jacobsen P, Fisher E, Bentsen KD. Platelet aggregation release of ATP in patients with hepatic cirrhosis. Scand J Gastroenterol 1985; 20: 285-288.